Emerging patterns suggest Moderna's two-dose vaccine might have a slight edge over Pfizer's in the long run.

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.

The company plans to submit authorization filing to the US FDA before Thanksgiving, Pfizer CEO Albert Bourla said.

Sanofi has sued Pfizer and Moderna , alleging that their COVID-19 vaccines infringe several of the French pharmaceutical company's patents.

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were both leaders in the coronavirus vaccine market. However, as sales of these products have declined significantly in recent years -- due to the ...

It is the first flu vaccine that uses mRNA technology, similar to Pfizer and Moderna's COVID vaccines.

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by Pfizer (PFE) and BioNTech (BNTX), marking the latest such case among ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has ...

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTec ...